Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Paris
Clinical trial register · France

Clinical Trials in Paris, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9722 matching records held by the registry are in this view. Synced 29 Oct 2026, 03:20 UTC
9722
Studies in scope
all four open statuses
6047
Recruiting now
open to new participants
1031
Lead sponsors
across recruiting studies
Top sites
Paris 68 Marseille 36 Bordeaux 35 Montpellier 32 Lille 31
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Assistance Publique - Hôpitaux de Paris604 Novartis Pharmaceuticals68 Fondation Ophtalmologique Adolphe de Rothschild67 Institut National de la Santé Et de la Recherche Médicale, France64 AstraZeneca64 Clear sponsor filter
Site location
Paris68 Marseille36 Bordeaux35 Montpellier32 Lille31
All 73 locations
Target enrolment
to

Trials with a site in Paris

68 of 9722 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Caen, Créteil, Lille, Marseille, Nantes, Paris, Rennes, Toulouse
2026-06-03
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Brest, Le Kremlin-Bicêtre, Lens, Nîmes, Paris, Pessac, Poitiers, Rennes
2026-05-27
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Bron, Chambray-lès-Tours, Compiègne, Grenoble, Le Coudray, Nantes, Paris, Toulouse
2026-05-11
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugsAsciminib single agent·ABL001
Novartis Pharmaceuticals
Phase 2
50
Marseille, Paris, Poitiers, Strasbourg
2026-04-28
Recruiting
Remibrutinib Open Label Roll-over Post-trial Access Protocol
NCT07456891Indication of the Parent Protocol
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
650
Bordeaux, Brest, Montpellier, Paris, Pierre-Bénite, Rouen
2026-04-16
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Lyon, Créteil, Dijon, Paris
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 2
30
Bordeaux, Bron, Le Kremlin-Bicêtre, Lille, Paris
2025-11-03
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Bordeaux, Paris
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 2
140
Angers, Bron, Dijon, Montpellier, Paris, Toulouse, Tours
2025-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
97
Toulouse, Paris
2025-08-07
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Bordeaux, Clermont-Ferrand, Lille, Marseille, Nice, Nîmes, Paris, Poitiers
2025-06-23
Active, closed
Novartis Pharmaceuticals
Phase 1
57
Brest, Le Kremlin-Bicêtre, Paris
2025-06-12
Recruiting
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
NCT06865651Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 2
44
Grenoble, Montpellier, Paris, Pierre-Bénite
2025-05-22
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Brest, Lille, Lorient, Paris, Pierre-Bénite, Reims, Rouen
2025-05-16
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Béziers, Cholet, Grenoble, Lille, Montpellier, Paris, Pessac, Poitiers
2025-04-30
Recruiting
Novartis Pharmaceuticals
Phase 2
20
Bordeaux, Lille, Lyon, Nantes, Paris, Vandœuvre-lès-Nancy
2025-02-18
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Bordeaux, Nice, Paris, Strasbourg, Toulouse
2025-02-07
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Brest, Lille, Lyon, Marseille, Paris, Rennes
2024-12-17
Recruiting
Novartis Pharmaceuticals
Phase 3
60
Marseille, Nantes, Paris
2024-12-09
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Bordeaux, Dijon, Lille, Lyon, Montpellier, Paris, Rennes, Strasbourg
2024-10-29
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Bron, Lille, Nice, Paris, Tours
2024-10-17
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Dijon, Le Mans, Lille, Montpellier, Paris, Rennes, Strasbourg, Toulouse
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Bordeaux, Clermont-Ferrand, Marseille, Montpellier, Nantes, Paris, Strasbourg, Toulouse
2024-09-04
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
DrugsIptacopan·Rituximab
Novartis Pharmaceuticals
Phase 2
84
Angers, Brest, Dijon, Marseille, Paris, Toulouse
2024-08-05
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Limoges, Garches, Nice, Paris
2024-07-31
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Montpellier, Paris, Toulouse
2024-05-21
Active, closed
Novartis Pharmaceuticals
Phase 2
23
Paris, Vandœuvre-lès-Nancy
2024-04-04
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Paris, Pessac, Poitiers, Rennes
2024-03-07
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Bordeaux, Paris, Rouen, Toulouse, Tours
2024-02-28
Active, closed
Novartis Pharmaceuticals
Observational
302
Angers, Paris, Agen, Altkirch, Amiens, Belfort, Bordeaux, Boulogne-sur-Mer
2023-12-21
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Grenoble, Montpellier, Nantes, Paris, Pierre-Bénite, Rouen, Toulouse
2023-12-07
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Angers, Brest, Dijon, Le Kremlin-Bicêtre, Le Mans, Lille, Paris, Saint-Priest-en-Jarez
2023-10-27
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Marseille, Montpellier, Paris, Rennes, Toulouse
2023-10-02
Active, closed
Novartis Pharmaceuticals
Phase 2
144
Angers, Marseille, Paris
2023-08-25
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Nîmes, Lille, Lyon, Grenoble, Paris
2023-07-06
Active, closed
Novartis Pharmaceuticals
Phase 1
71
Grenoble, Nantes, Paris
2023-05-08
Active, closed
Novartis Pharmaceuticals
Phase 3
288
Montpellier, Paris, Toulouse, Tours
2023-04-21
Active, closed
Novartis Pharmaceuticals
Phase 4
240
Chambray-lès-Tours, Le Mans, Nice, Paris
2023-03-28
Active, closed
Novartis Pharmaceuticals
Phase 1
38
Lille, Paris, Toulouse
2023-02-23
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Angers, Antony, Bordeaux, Brest, Montpellier, Nice, Paris, Pierre-Bénite
2022-12-09
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Bordeaux, Lyon, Marseille, Nantes, Paris, Vandœuvre-lès-Nancy
2022-08-30
Active, closed
Novartis Pharmaceuticals
Phase 3
610
Paris, Pessac, Poitiers, Toulouse
2022-07-08
Active, closed
Novartis Pharmaceuticals
Phase 1/2
66
Paris
2022-07-04
Active, closed
Novartis Pharmaceuticals
Phase 2
41
Dijon, Montpellier, Paris
2022-01-27
Recruiting
Novartis Pharmaceuticals
Phase 1/2
34
Bordeaux, Lille, Paris, Poitiers
2021-12-27
Active, closed
Novartis Pharmaceuticals
Phase 3
210
Besançon, Clermont-Ferrand, La Roche-sur-Yon, Lyon, Marseille, Montpellier, Paris, Valenciennes
2021-12-17
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Bordeaux, Lyon, Nantes, Paris
2021-10-06
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Marseille, Montpellier, Paris
2021-09-20
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Lille, Marseille, Montpellier, Paris
2021-07-28
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Lille, Nantes, Nice, Paris, Toulouse
2021-07-27
Active, closed
Novartis Pharmaceuticals
Phase 3
469
Angers, Bordeaux, Clermont-Ferrand, Lyon, Paris, Villejuif
2021-06-15
Recruiting
Novartis Pharmaceuticals
Phase 4
130
Créteil, Paris
2021-06-10
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
Bordeaux, Clermont-Ferrand, Lyon, Montpellier, Nantes, Paris, Strasbourg, Vandœuvre-lès-Nancy
2021-06-09
Active, closed
Novartis Pharmaceuticals
Phase 2
236
Bordeaux, Dijon, Paris, Tours
2021-04-19
Active, closed
Novartis Pharmaceuticals
Phase 2
17
Paris
2020-12-18
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Grenoble, Le Puy-en-Velay, Paris, Saint-Priest-en-Jarez, Valenciennes
2020-12-11
Active, closed
Novartis Pharmaceuticals
Phase 2
134
Lille, Marseille, Paris, Pierre-Bénite, Toulouse, Villejuif
2020-10-30
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Rennes, Brest, Marseille, Paris, Vandœuvre-lès-Nancy, Villejuif
2019-11-04
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Montpellier, Paris, Toulouse
2019-10-03
Active, closed
Novartis Pharmaceuticals
Phase 3
253
Créteil, Marseille, Paris
2019-07-26
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
Marseille, Paris, Pierre-Bénite, Rennes
2019-06-26
Active, closed
Novartis Pharmaceuticals
Phase 2
121
Paris
2019-06-24
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Lille, Montpellier, Nantes, Nice, Nîmes, Paris, Strasbourg
2018-12-28
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Lyon, Nantes, Paris, Villejuif
2018-01-26
Active, closed
Novartis Pharmaceuticals
Phase 4
233
Paris, Saint-Herblain, Strasbourg, Villejuif
2015-12-11
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Nantes, Paris, Pessac, Pierre-Bénite, Strasbourg, Villejuif
2015-11-02
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Paris
2015-03-05
Active, closed
Novartis Pharmaceuticals
Phase 1/2
259
Marseille, Paris, Saint-Herblain
2013-10-22
Rows per page Showing 1–68 of 68
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-france/city/paris

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,722 studies in total at the last sync on 29 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 68 of those studies with a site in Paris that also match the filters currently applied.

How many clinical trials are recruiting in Paris?

25 of the 68 studies on this page are recruiting new participants as of the 29 Oct 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 43 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Paris), 68 studies
PhaseStudiesRecruitingShare
Phase 3301244.1%
Phase 222832.4%
Phase 47310.3%
Phase 1/2527.4%
Phase 1304.4%
Observational101.5%

Most active sponsors

Lead sponsors with the most studies (Paris)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals6825
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.